Introduction. Administration of the broad sp«:ific proleinase inhibitor aprotinin (Trasylol) is recommended as part of the therapeutic re gimen of various diseascs, e.g. in shock syndromes, hypcrfibrinolysis or acute pancn~atitis [I] . However, the attempt to demonstrate clinical efTeclivencss of aprotinin therapy by prospcctive controllcd dinical trials has proved to bc extremely difficult, probably duc to the lack of an assay system allowing a reliableestimation of effective inhibitor conccntrations in plasma (1] . Wc have established a chromogenic peptide subSlrate assay convenient for monitori ng the inhibitory effectivcness of apro_ tinin in plasma samples of paticnts undergoing inhibitor therapy. corrcsponding to 200 KI U/ml untreated plasma) by dilu tion of Ihis stock solution with aprotinin-frec normal plasma.
3. Photomelrie A ssay. Tbe reac tion mix tu re is prepared by pipetting the sampies in the .following order into therr':lOstated (37°C) I-ml-cuvettes placed III a photometer: 855 JlI Tns buffer (0.2 M, pH 8.2), 25 jll acid-treated normal plasma (" blank") or aprotinin-containing.plasma (standard or ~a~ents' sa.mples), a~d 20111 kallikreinsolullOn (1 K U). After 5mlllllleub~lIon ~1 37 C 100 Jll S-2266 solution (1.5 mM) is added and thc hnear lI~crease in absorbancc at 405 nm read eontinuously for at least 3 mm. The free enzyme aetivity (LlAjmi n) of thc sampie is eale~l~t~d in pcrcent of the "blank". The percent of free enzyme actlv~tlcs of thc standard sampies are plotted against their conccntratlOns of aprotinin, and the inhibitory aetivity of aprotinin in the patients' plasma is calculated from this standard curve.
Rcsul ts and Discussion. Evaluation oj the Assay. According to the standard eurve ( Fig. I) the lowest accurately measur~ble amount of aprotinin is about 20 kal1ikrein inhibitor units (KIU)/ml plasma (before acid treatment), i.e. 0.25 KJU per a~ay. If the aproti nin amount excecds 0.75 -1.0~JU per. as~ay, I?l~sm.a sampies should be dilu ted as folIows. Smce kalllkrem aCllvlty lS elevated l.23-fold (n = 90; C.V. = 7.2%) by addition of acid-Assay Principlc. In eontrast to endogcnous plasma proteinase inhibitors. aprotinin (Trasylol) is a very potent immediate inhibitor of porcine panereatic kallik rein (tissue kallikrein). Duc to acid treatment of plasma sampies obtained after i.v. infusion of aprotinin in vivo or addition oflhe inhihitor in vitro, aprotinin is the only measurable tissue kalli krcin inhibitor in these specimens. After ineubation of acid-trcated plasma with tissuc kallikrein in excess ovcr aprotinin, the remaining amount ofthe enzyme is determined by its amidolytic activity on the substrate H-D-Val-Leu-Arg-p NA (S-2266). The ratc at which pNA is rclcased is measured pholometrical1y at 405 nm with the jnitial rate method. Under the given eonditions thc substrate recognizcs exelusively the tissue kallikrein applied.
Reagents. 5-2266 is manufactured by Aß Kabi Diagnostica, Stockholm, Sweden. Poreine pancreatic kallikrein is available as a lyophilized research product from Bayer AG, Wuppcrtal-Elbcrfeld. FRG: Kininogenase Standard Pt. 2208 L (512.5 KU /ampoule). A stock solution of I KU/J-ll is preparcd by dissolving the residue in sterile 0.9% NaCI solution adjusted to pH 7.5 with lriethanolamine. AprOlinin (Trasylol) for prcparation of the standard curve is purchased as a sterile isotonic solution (ampoulc5 of200,OOO KI U/I 0 ml, pH 5) from Bayer AG, Leverkusen, FRG.
Procedure. J. Acid Tremment oj Plasma. Normal plasma or patients' plasma is incubated for 10min al 25°C with an equal volurne of 3 % (wj v) perchloric acid. After centrifugation the supernatant is neutralized with 5 M K 2 C0 3 , kepl at 4 -8°C for furthe r 30min and theTeafter cenuifuged again. The rcsulting supernatant is frozen at _20°C or bclow.
Standard
Cun'e. An samples are aeid-treated bcfore further use. Standard sampies are madc up from no rmal plasma supplemented with aprotinin (I00K IU/ml acid-treated plasma treated normal plasma, all dilutions of aprotinin~containing plasma sampies must bc made by aprotinin-frccplasma. Thereby always thc same amount of plasma (25 J-l1) is added to the test system. Dilution with buffeT or isotonic saline sol ution instead of plasma yields inhibitor eoncentrations whieh are to~ low. For 40KIU/mi the within-run imprecision was 1.8 -10.8% in g scrics, thc between-series imprecision (n = 8)~.4 %. Thc recovery for 20 -80KIU/ml was 90 -125 %. The aCld-lreated sampIes were stable for at least 1 monlh at -20°C and for 6 months at -70°C. No innuencc by repeated freezing and thawing (10 times) eould be observed. Plasma sampies without acid treatment cannot be used bccause of a 100 high and irregular stimulation of the kallikrein activi ty in the assay system. Clinical ApplicQlion. Continuous i.v. infusion of 250,000 KIU/h in pOlytraumatizcd patients rcsulted in a mean plasma eonccntration of 45 KI U/ml. This b 'eJ is equivalent 10 approx. I IlM aprolinin and thus elose to the concenlration of the endogenous lll-plasmin inhibitor level (0.9 ~M) in normal plasma. The aprotinin plasma level achievcd du ri ng inhi bitor Iherapy caused a signifiea nt reduetion of the fibrinogcn split products eompared to untreated but equal1y severely injured patients indicating a bcneficial effeet by suppressing systemic fibrinolysis.
Conclusion. Estimation of aprotinin in plasma wit h the describcd amidolytie assay ean bc aehieved wilhin 70 -80min and is, thcrefore convenient as a bcds.ide-control of high dose proteinase i~hibitor therapy. Morcover, an ELiSA for aprotinin dcve10ped simultaneously (MüllcT-Est~rl ~t al. this is~ue) ~llows the de tection of up to 0.2KIU/ml wlthm 4h and lS sUltable, therefore, for special purposes, e.g. retrospective studies and low dose inhibitor therapy.
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